Coherus BioSciences Key Executives
This section highlights Coherus BioSciences's key executives, including their titles and compensation details.
Find Contacts at Coherus BioSciences
(Showing 0 of )
Coherus BioSciences Earnings
This section highlights Coherus BioSciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-10 | $-0.10 | $-0.28 |
| Read Transcript | Q3 | 2024 | 2024-11-06 | $-0.10 | $-0.01 |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $-0.05 | $-0.32 |
| Read Transcript | Q4 | 2023 | 2024-03-13 | $-0.21 | $-0.62 |
| Read Transcript | Q3 | 2023 | 2023-11-07 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-02 | $-0.52 | $-0.38 |
| Read Transcript | Q1 | 2023 | 2023-05-08 | $-0.61 | $-0.75 |
Financial Statements
Access annual & quarterly financial statements for Coherus BioSciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $266.96M | $257.24M | $211.04M | $326.55M | $475.82M |
| Cost of Revenue | $117.55M | $162.78M | $70.08M | $57.59M | $37.67M |
| Gross Profit | $149.41M | $94.46M | $140.96M | $268.96M | $438.16M |
| Gross Profit Ratio | 55.97% | 36.72% | 66.79% | 82.36% | 92.08% |
| Research and Development Expenses | $93.34M | $109.44M | $199.36M | $363.11M | $142.76M |
| General and Administrative Expenses | $- | $- | $187.98M | $161.01M | $135.28M |
| Selling and Marketing Expenses | $- | $- | $10.50M | $8.70M | $3.80M |
| Selling General and Administrative Expenses | $167.74M | $185.62M | $198.48M | $169.71M | $139.08M |
| Other Expenses | $- | $- | $3.82M | $-283.00K | $554.00K |
| Operating Expenses | $261.07M | $301.45M | $397.84M | $532.82M | $281.84M |
| Cost and Expenses | $378.63M | $460.44M | $467.92M | $590.41M | $319.50M |
| Interest Income | $- | $- | $30.57M | $21.56M | $20.57M |
| Interest Expense | $27.16M | $40.54M | $32.47M | $22.96M | $21.17M |
| Depreciation and Amortization | $5.28M | $3.79M | $3.70M | $5.66M | $4.97M |
| EBITDA | $60.94M | $-193.94M | $-255.58M | $-260.69M | $161.84M |
| EBITDA Ratio | 22.83% | -75.39% | -121.10% | -79.83% | 34.01% |
| Operating Income | $-111.67M | $-203.20M | $-256.88M | $-263.86M | $156.32M |
| Operating Income Ratio | -41.83% | -78.99% | -121.72% | -80.80% | 32.85% |
| Total Other Income Expenses Net | $140.17M | $-35.07M | $-34.87M | $-23.24M | $-20.61M |
| Income Before Tax | $28.51M | $-238.27M | $-291.75M | $-287.10M | $135.71M |
| Income Before Tax Ratio | 10.68% | -92.62% | -138.24% | -87.92% | 28.52% |
| Income Tax Expense | $- | $-380.00K | $34.87M | $19.22M | $3.46M |
| Net Income | $28.51M | $-237.89M | $-326.63M | $-306.32M | $132.24M |
| Net Income Ratio | 10.68% | -92.48% | -154.77% | -93.81% | 27.79% |
| EPS | $0.25 | $-2.53 | $-4.21 | $-4.06 | $1.85 |
| EPS Diluted | $0.25 | $-2.53 | $-4.21 | $-4.06 | $1.62 |
| Weighted Average Shares Outstanding | 114.55M | 94.16M | 77.63M | 75.45M | 71.41M |
| Weighted Average Shares Outstanding Diluted | 114.83M | 94.16M | 77.63M | 75.45M | 83.49M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.14M | $70.77M | $64.98M | $77.06M | $91.52M | $74.57M | $58.72M | $32.44M | $45.35M | $45.42M | $60.15M | $60.12M | $73.37M | $82.50M | $87.64M | $83.03M | $110.42M | $113.55M | $135.67M | $116.18M |
| Cost of Revenue | $33.86M | $20.74M | $29.55M | $36.09M | $85.63M | $32.70M | $24.85M | $16.87M | $14.20M | $35.23M | $11.28M | $9.37M | $12.10M | $21.28M | $16.70M | $7.51M | $11.67M | $9.00M | $10.14M | $6.86M |
| Gross Profit | $20.29M | $50.03M | $35.42M | $40.97M | $5.89M | $41.87M | $33.87M | $15.56M | $31.15M | $10.19M | $48.87M | $50.74M | $61.27M | $61.22M | $70.95M | $75.52M | $98.75M | $104.55M | $125.53M | $109.33M |
| Gross Profit Ratio | 37.47% | 70.69% | 54.52% | 53.16% | 6.44% | 56.14% | 57.68% | 47.98% | 68.68% | 22.43% | 81.25% | 84.41% | 83.50% | 74.21% | 80.95% | 90.95% | 89.43% | 92.07% | 92.53% | 94.10% |
| Research and Development Expenses | $21.23M | $21.68M | $20.77M | $26.96M | $25.30M | $25.65M | $23.27M | $34.15M | $29.02M | $45.81M | $41.61M | $82.92M | $50.76M | $54.09M | $54.77M | $203.49M | $44.63M | $38.85M | $26.17M | $33.11M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $43.12M | $- | $- | $- | $41.35M | $- | $- | $- | $37.69M | $31.98M | $34.05M | $35.35M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $10.50M | $- | $- | $- | $8.70M | $- | $- | $- | $3.80M | $- | $- | $- |
| Selling General and Administrative Expenses | $41.30M | $34.74M | $35.16M | $49.73M | $48.95M | $48.22M | $45.14M | $49.15M | $53.62M | $44.83M | $51.28M | $48.75M | $50.05M | $39.92M | $40.34M | $39.39M | $37.69M | $31.98M | $34.05M | $35.35M |
| Other Expenses | $- | $- | $1.47M | $2.87M | $-129.00K | $2.25M | $1.62M | $1.73M | $2.01M | $1.34M | $443.00K | $32.00K | $-385.00K | $30.00K | $11.00K | $61.00K | $6.00K | $56.00K | $423.00K | $68.00K |
| Operating Expenses | $62.53M | $56.42M | $55.93M | $76.69M | $74.25M | $73.87M | $68.41M | $83.31M | $82.64M | $90.64M | $92.89M | $131.67M | $100.81M | $94.01M | $95.11M | $242.88M | $82.32M | $70.83M | $60.23M | $68.46M |
| Cost and Expenses | $96.39M | $77.16M | $85.49M | $112.79M | $159.88M | $106.57M | $93.26M | $100.18M | $96.84M | $125.87M | $104.16M | $141.04M | $112.92M | $115.29M | $111.81M | $250.39M | $93.99M | $79.83M | $70.36M | $75.31M |
| Interest Income | $- | $- | $- | $- | $- | $10.27M | $9.94M | $9.71M | $7.49M | $7.54M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $5.35M | $5.36M | $5.33M | $11.12M | $10.62M | $10.27M | $9.94M | $9.71M | $9.38M | $7.54M | $6.58M | $8.97M | $5.79M | $5.77M | $5.75M | $5.65M | $5.67M | $5.66M | $5.41M | $4.43M |
| Depreciation and Amortization | $1.03M | $1.55M | $1.19M | $1.51M | $1.06M | $1.64M | $880.00K | $949.00K | $1.05M | $900.00K | $900.00K | $767.00K | $1.43M | $1.45M | $1.44M | $1.38M | $840.00K | $693.00K | $748.00K | $607.00K |
| EBITDA | $-44.32M | $-3.84M | $-6.40M | $-30.42M | $-67.97M | $-28.12M | $-32.05M | $-65.07M | $-48.44M | $-78.21M | $-42.67M | $-86.35M | $-38.51M | $-31.30M | $-23.28M | $-165.92M | $17.27M | $34.41M | $66.06M | $41.48M |
| EBITDA Ratio | -81.85% | -5.43% | -9.85% | -39.47% | -74.27% | -37.71% | -54.58% | -200.60% | -106.80% | -172.18% | -70.94% | -143.64% | -52.48% | -37.94% | -26.56% | -199.83% | 15.64% | 30.30% | 48.69% | 35.70% |
| Operating Income | $-42.25M | $-6.39M | $-20.51M | $-35.73M | $-68.36M | $-32.01M | $-34.54M | $-67.75M | $-51.49M | $-80.45M | $-44.01M | $-80.92M | $-39.55M | $-32.79M | $-24.16M | $-167.36M | $16.43M | $33.72M | $65.31M | $40.87M |
| Operating Income Ratio | -78.03% | -9.02% | -31.56% | -46.36% | -74.69% | -42.92% | -58.83% | -208.86% | -113.54% | -177.11% | -73.17% | -134.62% | -53.90% | -39.74% | -27.57% | -201.56% | 14.88% | 29.69% | 48.14% | 35.18% |
| Total Other Income Expenses Net | $-8.45M | $-4.36M | $7.59M | $145.40M | $-10.75M | $-8.02M | $-8.33M | $-7.98M | $-7.38M | $-6.20M | $-6.14M | $-15.16M | $-6.18M | $-5.74M | $-5.74M | $-5.59M | $-5.67M | $-5.60M | $-4.99M | $-4.36M |
| Income Before Tax | $-50.70M | $-10.75M | $-12.92M | $102.88M | $-79.65M | $-40.02M | $-42.87M | $-75.73M | $-58.87M | $-86.65M | $-50.15M | $-96.08M | $-45.73M | $-38.53M | $-29.90M | $-172.95M | $10.76M | $28.12M | $60.33M | $36.51M |
| Income Before Tax Ratio | -93.63% | -15.19% | -19.88% | 133.49% | -87.03% | -53.67% | -73.01% | -233.47% | -129.81% | -190.76% | -83.37% | -159.83% | -62.32% | -46.70% | -34.12% | -208.28% | 9.74% | 24.76% | 44.46% | 31.42% |
| Income Tax Expense | $- | $- | $- | $1.46M | $-10.61M | $-380.00K | $11.56M | $-949.00K | $7.38M | $6.20M | $6.14M | $15.16M | $5.79M | $5.80M | $5.76M | $5.71M | $1.05M | $183.00K | $1.29M | $933.00K |
| Net Income | $-50.70M | $-10.75M | $-12.92M | $102.88M | $-79.65M | $-39.64M | $-42.87M | $-74.78M | $-66.25M | $-92.85M | $-56.29M | $-111.24M | $-45.73M | $-38.53M | $-29.90M | $-172.95M | $9.71M | $27.93M | $59.03M | $35.57M |
| Net Income Ratio | -93.63% | -15.19% | -19.88% | 133.49% | -87.03% | -53.16% | -73.01% | -230.55% | -146.07% | -204.41% | -93.58% | -185.05% | -62.32% | -46.70% | -34.12% | -208.28% | 8.79% | 24.60% | 43.51% | 30.62% |
| EPS | $-0.44 | $-0.09 | $-0.11 | $0.91 | $-0.71 | $-0.41 | $-0.49 | $-0.94 | $-0.85 | $-1.19 | $-0.73 | $-1.44 | $-0.60 | $-0.49 | $-0.40 | $-2.37 | $0.13 | $0.39 | $0.83 | $0.50 |
| EPS Diluted | $-0.44 | $-0.09 | $-0.11 | $0.82 | $-0.71 | $-0.41 | $-0.49 | $-0.94 | $-0.85 | $-1.19 | $-0.73 | $-1.44 | $-0.60 | $-0.49 | $-0.40 | $-2.37 | $0.12 | $0.33 | $0.70 | $0.48 |
| Weighted Average Shares Outstanding | 115.42M | 115.21M | 114.82M | 112.75M | 111.49M | 97.74M | 87.27M | 79.27M | 77.96M | 77.75M | 77.15M | 77.25M | 76.35M | 78.63M | 75.56M | 72.83M | 72.22M | 71.65M | 71.10M | 70.66M |
| Weighted Average Shares Outstanding Diluted | 115.42M | 115.21M | 114.82M | 125.53M | 111.49M | 97.74M | 87.27M | 79.27M | 77.96M | 77.75M | 77.55M | 77.25M | 76.83M | 79.01M | 75.56M | 72.83M | 87.71M | 87.47M | 88.66M | 74.42M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $125.99M | $102.89M | $63.55M | $417.19M | $541.16M |
| Short Term Investments | $- | $14.86M | $128.13M | $- | $- |
| Cash and Short Term Investments | $125.99M | $117.75M | $191.68M | $417.19M | $541.16M |
| Net Receivables | $122.33M | $260.52M | $109.96M | $123.02M | $157.05M |
| Inventory | $70.09M | $62.60M | $115.05M | $93.25M | $92.19M |
| Other Current Assets | $23.17M | $34.76M | $40.80M | $24.46M | $25.04M |
| Total Current Assets | $341.58M | $475.63M | $416.70M | $633.47M | $790.39M |
| Property Plant Equipment Net | $2.84M | $11.03M | $8.75M | $7.81M | $20.06M |
| Goodwill | $- | $943.00K | $900.00K | $943.00K | $943.00K |
| Intangible Assets | $53.65M | $70.73M | $5.03M | $2.62M | $2.62M |
| Goodwill and Intangible Assets | $53.65M | $71.67M | $5.93M | $3.56M | $3.56M |
| Long Term Investments | $- | $- | $440.00K | $440.00K | $440.00K |
| Tax Assets | $- | $- | $-440.00K | $-440.00K | $-440.00K |
| Other Non-Current Assets | $50.47M | $71.27M | $49.47M | $34.49M | $27.63M |
| Total Non-Current Assets | $106.95M | $153.97M | $64.15M | $45.87M | $51.26M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $448.53M | $629.60M | $480.85M | $679.33M | $841.65M |
| Account Payables | $28.46M | $35.22M | $11.53M | $16.16M | $15.20M |
| Short Term Debt | $1.69M | $2.15M | $4.32M | $3.49M | $3.13M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $-3.13M |
| Other Current Liabilities | $252.83M | $294.41M | $122.85M | $145.68M | $127.32M |
| Total Current Liabilities | $282.98M | $331.77M | $54.46M | $79.03M | $81.53M |
| Long Term Debt | $231.51M | $478.70M | $476.10M | $415.53M | $413.97M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $1.10M | $1.10M | $- | $- | $- |
| Other Non-Current Liabilities | $64.92M | $11.46M | $3.47M | $750.00K | $1.05M |
| Total Non-Current Liabilities | $297.54M | $491.26M | $563.80M | $502.58M | $479.15M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $580.52M | $823.03M | $618.26M | $581.61M | $560.67M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $12.00K | $11.00K | $8.00K | $7.00K | $7.00K |
| Retained Earnings | $-1.55B | $-1.58B | $-1.34B | $-1.05B | $-762.75M |
| Accumulated Other Comprehensive Income Loss | $-275.00K | $-248.00K | $-249.00K | $-270.00K | $-270.00K |
| Other Total Stockholders Equity | $1.42B | $1.39B | $1.20B | $1.15B | $1.04B |
| Total Stockholders Equity | $-131.99M | $-193.43M | $-137.42M | $97.73M | $280.97M |
| Total Equity | $-131.99M | $-193.43M | $-137.42M | $97.73M | $280.97M |
| Total Liabilities and Stockholders Equity | $448.53M | $629.60M | $480.85M | $679.33M | $841.65M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $448.53M | $629.60M | $480.85M | $679.33M | $841.65M |
| Total Investments | $- | $14.86M | $128.13M | $440.00K | $440.00K |
| Total Debt | $231.51M | $480.84M | $471.06M | $408.28M | $404.02M |
| Net Debt | $105.53M | $377.95M | $407.51M | $-8.91M | $-137.13M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $125.99M | $97.69M | $159.24M | $259.77M | $102.89M | $80.26M | $72.92M | $16.14M | $63.55M | $286.81M | $275.48M | $325.68M | $417.19M | $360.54M | $329.74M | $259.49M | $541.16M | $292.46M | $224.62M | $193.25M |
| Short Term Investments | $- | $- | $- | $- | $14.86M | $50.82M | $71.79M | $111.94M | $128.13M | $- | $- | $- | $- | $108.17M | $124.68M | $140.01M | $- | $210.97M | $231.88M | $- |
| Cash and Short Term Investments | $125.99M | $97.69M | $159.24M | $259.77M | $117.75M | $131.08M | $144.71M | $128.09M | $191.68M | $286.81M | $275.48M | $325.68M | $417.19M | $468.71M | $454.42M | $399.50M | $541.16M | $503.43M | $456.50M | $193.25M |
| Net Receivables | $111.32M | $198.80M | $313.57M | $284.14M | $260.52M | $216.51M | $141.31M | $101.46M | $109.96M | $91.19M | $115.71M | $117.04M | $123.02M | $136.35M | $141.82M | $140.41M | $157.05M | $160.71M | $172.49M | $167.45M |
| Inventory | $113.87M | $47.64M | $62.16M | $61.98M | $62.60M | $66.78M | $63.99M | $114.49M | $115.05M | $27.72M | $31.74M | $36.95M | $93.25M | $37.58M | $39.67M | $51.61M | $92.19M | $35.25M | $80.98M | $16.44M |
| Other Current Assets | $- | $24.89M | $22.96M | $21.58M | $34.76M | $29.99M | $35.48M | $36.97M | $40.80M | $42.56M | $23.84M | $32.78M | $24.46M | $30.40M | $24.10M | $25.73M | $25.04M | $27.54M | $19.68M | $18.05M |
| Total Current Assets | $351.18M | $369.02M | $557.93M | $627.48M | $475.63M | $444.37M | $385.48M | $344.03M | $416.70M | $448.27M | $446.78M | $512.44M | $633.47M | $673.04M | $660.01M | $617.26M | $790.39M | $726.92M | $709.97M | $395.18M |
| Property Plant Equipment Net | $- | $2.91M | $3.33M | $4.19M | $11.03M | $6.07M | $6.93M | $7.72M | $8.75M | $9.57M | $9.55M | $8.00M | $7.81M | $8.51M | $9.13M | $9.67M | $20.06M | $21.12M | $21.32M | $18.36M |
| Goodwill | $- | $- | $- | $- | $943.00K | $943.00K | $- | $- | $900.00K | $- | $- | $- | $943.00K | $943.00K | $943.00K | $943.00K | $943.00K | $943.00K | $943.00K | $943.00K |
| Intangible Assets | $53.65M | $54.31M | $55.45M | $57.10M | $70.73M | $45.58M | $5.81M | $5.87M | $5.03M | $6.00M | $3.56M | $3.56M | $2.62M | $2.62M | $2.62M | $2.62M | $2.62M | $2.62M | $2.62M | $2.62M |
| Goodwill and Intangible Assets | $53.65M | $54.31M | $55.45M | $57.10M | $71.67M | $46.52M | $5.81M | $5.87M | $5.93M | $6.00M | $3.56M | $3.56M | $3.56M | $3.56M | $3.56M | $3.56M | $3.56M | $3.56M | $3.56M | $3.56M |
| Long Term Investments | $- | $- | $452.00K | $452.00K | $452.00K | $- | $- | $- | $440.00K | $- | $- | $- | $440.00K | $- | $- | $- | $- | $210.97M | $- | $- |
| Tax Assets | $- | $- | $-1 | $- | $70.73M | $- | $- | $- | $-440.00K | $- | $- | $- | $-440.00K | $- | $- | $- | $- | $-210.97M | $- | $- |
| Other Non-Current Assets | $- | $78.75M | $57.68M | $74.32M | $87.00K | $86.83M | $71.37M | $44.80M | $49.47M | $87.06M | $86.10M | $69.38M | $34.49M | $56.62M | $66.84M | $62.81M | $27.63M | $52.13M | $21.76M | $49.43M |
| Total Non-Current Assets | $53.65M | $135.98M | $116.92M | $136.07M | $153.97M | $139.42M | $84.11M | $58.39M | $64.15M | $102.63M | $99.22M | $80.94M | $45.87M | $68.69M | $79.53M | $76.04M | $51.26M | $76.81M | $46.64M | $71.36M |
| Other Assets | $43.71M | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $448.53M | $505.00M | $674.86M | $763.54M | $629.60M | $583.78M | $469.59M | $402.43M | $480.85M | $550.91M | $546.00M | $593.39M | $679.33M | $741.73M | $739.54M | $693.30M | $841.65M | $803.73M | $756.61M | $466.54M |
| Account Payables | $28.46M | $21.89M | $76.82M | $38.29M | $35.22M | $37.09M | $29.28M | $23.23M | $11.53M | $9.92M | $17.49M | $21.09M | $16.16M | $45.71M | $14.57M | $15.48M | $15.20M | $11.99M | $21.18M | $20.48M |
| Short Term Debt | $1.69M | $1.63M | $1.44M | $176.81M | $2.15M | $4.47M | $4.45M | $4.44M | $4.32M | $4.10M | $3.99M | $3.37M | $3.49M | $128.90M | $122.42M | $110.28M | $3.13M | $- | $2.92M | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $136.66M | $- | $-4.47M | $-4.45M | $- | $- | $- | $- | $- | $-86.30M | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $252.83M | $272.04M | $384.75M | $323.20M | $294.41M | $198.10M | $135.72M | $95.74M | $122.85M | $157.31M | $119.28M | $129.29M | $145.68M | $145.74M | $150.06M | $131.84M | $127.32M | $121.44M | $105.67M | $98.53M |
| Total Current Liabilities | $282.98M | $295.57M | $463.00M | $538.30M | $331.77M | $239.66M | $169.44M | $55.70M | $54.46M | $171.32M | $140.75M | $153.75M | $79.03M | $320.35M | $287.05M | $257.60M | $81.53M | $133.43M | $66.23M | $119.01M |
| Long Term Debt | $268.21M | $231.63M | $294.22M | $304.35M | $478.70M | $474.21M | $474.81M | $475.42M | $476.10M | $476.62M | $427.78M | $426.97M | $415.53M | $289.87M | $295.52M | $307.28M | $413.97M | $413.76M | $413.37M | $190.15M |
| Deferred Revenue Non-Current | $- | $- | $4.16M | $-352.86M | $5.33M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $1.10M | $1.10M | $1.10M | $1.10M | $1.10M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $28.23M | $64.68M | $632.00K | $1.63M | $11.46M | $3.51M | $102.00K | $102.00K | $3.47M | $102.00K | $102.00K | $102.00K | $750.00K | $750.00K | $751.00K | $750.00K | $1.05M | $807.00K | $102.00K | $102.00K |
| Total Non-Current Liabilities | $297.54M | $297.41M | $295.96M | $307.09M | $491.26M | $477.72M | $474.92M | $543.24M | $563.80M | $476.72M | $427.88M | $427.08M | $502.58M | $290.62M | $296.27M | $308.03M | $479.15M | $414.57M | $477.00M | $190.25M |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $580.52M | $592.97M | $758.96M | $845.39M | $823.03M | $717.38M | $644.36M | $598.93M | $618.26M | $648.04M | $568.63M | $580.82M | $581.61M | $610.97M | $583.32M | $565.63M | $560.67M | $548.00M | $543.23M | $309.26M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $12.00K | $12.00K | $11.00K | $11.00K | $11.00K | $9.00K | $8.00K | $8.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K |
| Retained Earnings | $-1.55B | $-1.50B | $-1.49B | $-1.48B | $-1.58B | $-1.50B | $-1.46B | $-1.42B | $-1.34B | $-1.28B | $-1.20B | $-1.15B | $-1.05B | $-1.00B | $-965.60M | $-935.70M | $-762.75M | $-772.46M | $-800.39M | $-859.43M |
| Accumulated Other Comprehensive Income Loss | $-275.00K | $-275.00K | $-272.00K | $-272.00K | $-248.00K | $-265.00K | $-297.00K | $-278.00K | $-249.00K | $-270.00K | $-270.00K | $-272.00K | $-270.00K | $-273.00K | $-267.00K | $-307.00K | $-270.00K | $-255.00K | $-257.00K | $50.00K |
| Other Total Stockholders Equity | $1.42B | $1.41B | $1.41B | $1.40B | $1.39B | $1.37B | $1.29B | $1.22B | $1.20B | $1.19B | $1.17B | $1.16B | $1.15B | $1.14B | $1.12B | $1.06B | $1.04B | $1.03B | $1.01B | $1.02B |
| Total Stockholders Equity | $-131.99M | $-87.97M | $-84.11M | $-81.84M | $-193.43M | $-133.60M | $-174.76M | $-196.51M | $-137.42M | $-97.13M | $-22.63M | $12.56M | $97.73M | $130.76M | $156.22M | $127.67M | $280.97M | $255.73M | $213.38M | $157.28M |
| Total Equity | $-131.99M | $-87.97M | $-84.11M | $-81.84M | $-193.43M | $-133.60M | $-174.76M | $-196.51M | $-137.42M | $-97.13M | $-22.63M | $12.56M | $97.73M | $130.76M | $156.22M | $127.67M | $280.97M | $255.73M | $213.38M | $157.28M |
| Total Liabilities and Stockholders Equity | $448.53M | $505.00M | $674.86M | $763.54M | $629.60M | $583.78M | $469.59M | $402.43M | $480.85M | $550.91M | $546.00M | $593.39M | $679.33M | $741.73M | $739.54M | $693.30M | $841.65M | $803.73M | $756.61M | $466.54M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $448.53M | $505.00M | $674.86M | $763.54M | $629.60M | $583.78M | $469.59M | $402.43M | $480.85M | $550.91M | $546.00M | $593.39M | $679.33M | $741.73M | $739.54M | $693.30M | $841.65M | $803.73M | $756.61M | $466.54M |
| Total Investments | $- | $- | $452.00K | $452.00K | $15.31M | $50.82M | $71.79M | $111.94M | $128.13M | $- | $- | $- | $440.00K | $108.17M | $124.68M | $140.01M | $- | $421.93M | $231.88M | $- |
| Total Debt | $269.90M | $231.63M | $298.34M | $481.16M | $480.84M | $478.68M | $479.26M | $471.62M | $471.06M | $480.72M | $431.76M | $430.34M | $408.28M | $418.77M | $417.94M | $417.56M | $404.02M | $413.76M | $402.06M | $190.15M |
| Net Debt | $143.92M | $133.94M | $139.10M | $221.39M | $377.95M | $398.42M | $406.34M | $455.47M | $407.51M | $193.91M | $156.28M | $104.66M | $-8.91M | $58.23M | $88.20M | $158.07M | $-137.13M | $121.30M | $177.45M | $-3.10M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $28.51M | $-237.89M | $-291.75M | $-287.10M | $132.24M |
| Depreciation and Amortization | $5.28M | $3.79M | $3.70M | $3.45M | $2.89M |
| Deferred Income Tax | $- | $- | $- | $9.44M | $-155.00K |
| Stock Based Compensation | $27.80M | $43.11M | $50.74M | $51.36M | $38.16M |
| Change in Working Capital | $55.89M | $-36.83M | $-79.26M | $42.36M | $-32.48M |
| Accounts Receivables | $- | $-150.68M | $13.05M | $34.06M | $-15.22M |
| Inventory | $- | $-46.73M | $-47.35M | $-6.25M | $-36.19M |
| Accounts Payables | $-3.94M | $23.76M | $-4.55M | $874.00K | $-9.82M |
| Other Working Capital | $59.83M | $136.83M | $-40.41M | $13.68M | $28.75M |
| Other Non Cash Items | $-137.92M | $52.93M | $75.45M | $143.05M | $5.99M |
| Net Cash Provided by Operating Activities | $-20.44M | $-174.88M | $-241.12M | $-37.43M | $154.15M |
| Investments in Property Plant and Equipment | $- | $-286.00K | $-2.04M | $-1.29M | $-7.06M |
| Acquisitions Net | $- | $845.00K | $- | $1.29M | $175.00K |
| Purchases of Investments | $- | $-19.51M | $-127.38M | $-182.49M | $-273.85M |
| Sales Maturities of Investments | $14.89M | $157.64M | $- | $181.36M | $274.00M |
| Other Investing Activities | $215.43M | $5.95M | $-37.43M | $-137.29M | $-7.67M |
| Net Cash Used for Investing Activities | $230.32M | $144.64M | $-166.85M | $-138.41M | $-14.40M |
| Debt Repayment | $-223.41M | $- | $49.93M | $- | $222.16M |
| Common Stock Issued | $1.46M | $74.22M | $6.36M | $40.90M | $21.23M |
| Common Stock Repurchased | $- | $- | $- | $- | $-880.00K |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $34.98M | $-2.12M | $-1.96M | $10.98M | $1.79M |
| Net Cash Used Provided by Financing Activities | $-186.97M | $69.60M | $54.33M | $51.88M | $223.95M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $22.91M | $39.36M | $-353.65M | $-123.96M | $363.69M |
| Cash at End of Period | $126.25M | $103.34M | $63.99M | $417.63M | $541.60M |
| Cash at Beginning of Period | $103.34M | $63.99M | $417.63M | $541.60M | $177.91M |
| Operating Cash Flow | $-20.44M | $-174.88M | $-241.12M | $-37.43M | $154.15M |
| Capital Expenditure | $- | $-286.00K | $-2.04M | $-1.29M | $-7.06M |
| Free Cash Flow | $-20.44M | $-175.17M | $-243.16M | $-38.72M | $147.09M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $- | $-10.75M | $-12.92M | $102.88M | $-79.65M | $-39.64M | $-42.87M | $-75.73M | $-58.87M | $-86.65M | $-50.15M | $-96.08M | $-45.73M | $-38.53M | $-29.90M | $-172.95M | $9.71M | $27.93M | $59.03M | $35.57M |
| Depreciation and Amortization | $1.03M | $1.55M | $1.19M | $1.51M | $1.06M | $899.00K | $880.00K | $949.00K | $1.05M | $995.00K | $887.00K | $767.00K | $836.00K | $892.00K | $877.00K | $849.00K | $840.00K | $693.00K | $748.00K | $607.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-69.56M | $874.00K | $-1.24M | $- | $- | $- | $- | $- | $127.00K | $5.45M | $370.00K | $3.49M | $-52.00K | $-103.00K | $- | $- |
| Stock Based Compensation | $- | $6.87M | $7.23M | $7.32M | $10.80M | $9.95M | $10.08M | $12.28M | $11.73M | $12.28M | $13.85M | $12.88M | $10.95M | $11.94M | $11.60M | $16.88M | $17.37M | $9.31M | $9.43M | $9.55M |
| Change in Working Capital | $54.54M | $-62.89M | $74.26M | $-11.38M | $6.37M | $-27.62M | $-6.23M | $-9.35M | $-54.61M | $8.69M | $-16.22M | $-17.12M | $-20.61M | $32.32M | $24.26M | $6.39M | $11.25M | $5.43M | $-15.13M | $-34.03M |
| Accounts Receivables | $56.33M | $7.81M | $76.64M | $8.58M | $-44.06M | $-75.28M | $-39.88M | $8.53M | $-18.80M | $24.52M | $1.34M | $5.99M | $13.34M | $5.48M | $-1.42M | $16.66M | $3.67M | $11.79M | $-5.05M | $-25.63M |
| Inventory | $- | $21.04M | $-7.10M | $-11.46M | $-11.79M | $-19.23M | $-13.04M | $-2.67M | $-9.79M | $-23.35M | $-11.24M | $-2.96M | $-9.19M | $6.80M | $7.52M | $-11.38M | $-6.13M | $-4.82M | $-15.63M | $-9.61M |
| Accounts Payables | $- | $-50.36M | $39.46M | $616.00K | $-785.00K | $6.76M | $6.05M | $11.74M | $1.60M | $-7.57M | $-3.33M | $4.76M | $-29.62M | $31.27M | $-976.00K | $203.00K | $3.29M | $-7.98M | $-173.00K | $-4.96M |
| Other Working Capital | $-1.79M | $-41.37M | $-34.73M | $-9.12M | $63.00M | $60.12M | $40.65M | $-26.94M | $-27.62M | $15.10M | $-2.98M | $-24.90M | $4.86M | $-11.22M | $19.14M | $904.00K | $10.43M | $6.43M | $5.72M | $6.16M |
| Other Non Cash Items | $-26.96M | $3.20M | $-109.42M | $-134.50M | $118.05M | $1.24M | $468.00K | $3.11M | $754.00K | $27.59M | $1.60M | $45.51M | $2.10M | $1.64M | $-7.39M | $146.70M | $-5.99M | $4.09M | $6.11M | $1.77M |
| Net Cash Provided by Operating Activities | $28.61M | $-62.02M | $59.73M | $-46.77M | $-12.94M | $-54.30M | $-38.91M | $-68.73M | $-99.95M | $-37.09M | $-50.04M | $-54.05M | $-52.32M | $13.71M | $-188.00K | $1.37M | $33.12M | $47.35M | $60.19M | $13.48M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $-34.00K | $- | $-100.00K | $-152.00K | $-87.00K | $-457.00K | $-880.00K | $-615.00K | $-468.00K | $-261.00K | $-415.00K | $-145.00K | $-944.00K | $-2.11M | $-2.38M | $-1.78M |
| Acquisitions Net | $- | $- | $227.82M | $- | $76.00K | $151.00K | $440.00K | $178.00K | $- | $- | $- | $- | $468.00K | $261.00K | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $178.00K | $- | $-19.51M | $-178.00K | $-127.38M | $- | $- | $- | $-10.71M | $-31.45M | $- | $-140.33M | $- | $-41.98M | $-231.86M | $- |
| Sales Maturities of Investments | $- | $- | $227.82M | $14.89M | $36.21M | $43.40M | $60.53M | $17.50M | $- | $- | $- | $- | $118.66M | $47.70M | $- | $- | $211.00M | $63.00M | $- | $- |
| Other Investing Activities | $-542.00K | $444.00K | $-200.17M | $187.88M | $-1.05M | $7.00M | $41.47M | $178.00K | $-2.43M | $-457.00K | $-880.00K | $-35.00M | $-468.00K | $-261.00K | $24.00M | $-145.00M | $211.01M | $-2.50M | $-5.00M | $167.00K |
| Net Cash Used for Investing Activities | $-542.00K | $444.00K | $27.66M | $202.76M | $35.20M | $50.55M | $41.37M | $17.53M | $-129.90M | $-457.00K | $-880.00K | $-35.62M | $107.49M | $15.99M | $23.59M | $-285.48M | $210.06M | $16.41M | $-239.25M | $-1.62M |
| Debt Repayment | $- | $-141.00K | $-186.77M | $- | $- | $- | $- | $- | $- | $49.49M | $- | $440.00K | $- | $- | $- | $- | $- | $-674.00K | $222.83M | $- |
| Common Stock Issued | $- | $-976.00K | $633.00K | $1.51M | $-105.00K | $11.44M | $53.55M | $6.83M | $6.36M | $79.00K | $8.00K | $544.00K | $40.90M | $1.28M | $47.01M | $4.33M | $17.43M | $- | $- | $- |
| Common Stock Repurchased | $- | $2.46M | $- | $- | $3.26M | $- | $- | $- | $- | $-321.00K | $-642.00K | $-2.66M | $-23.00K | $- | $- | $-1.73M | $- | $- | $- | $-880.00K |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $231.00K | $-26.00K | $-1.10M | $-620.00K | $471.00K | $-332.00K | $774.00K | $-3.03M | $235.00K | $-301.00K | $721.00K | $363.00K | $1.51M | $1.10M | $46.85M | $2.44M | $5.51M | $4.76M | $-12.41M | $3.92M |
| Net Cash Used Provided by Financing Activities | $231.00K | $-167.00K | $-187.93M | $887.00K | $366.00K | $11.11M | $54.33M | $3.80M | $6.59M | $48.87M | $721.00K | $-1.85M | $1.49M | $1.10M | $46.85M | $2.44M | $5.51M | $4.09M | $210.42M | $3.92M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-452.00K | $2.60M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $28.30M | $-61.29M | $-100.53M | $156.88M | $22.18M | $7.35M | $56.77M | $-47.40M | $-223.26M | $11.32M | $-50.20M | $-91.52M | $56.66M | $30.80M | $70.25M | $-281.67M | $248.69M | $67.85M | $31.36M | $15.78M |
| Cash at End of Period | $126.25M | $97.95M | $159.24M | $259.77M | $102.89M | $80.71M | $73.36M | $16.59M | $63.99M | $287.25M | $275.92M | $326.12M | $417.63M | $360.98M | $330.18M | $259.93M | $541.60M | $292.90M | $225.06M | $193.69M |
| Cash at Beginning of Period | $97.95M | $159.24M | $259.77M | $102.89M | $80.71M | $73.36M | $16.59M | $63.99M | $287.25M | $275.92M | $326.12M | $417.63M | $360.98M | $330.18M | $259.93M | $541.60M | $292.90M | $225.06M | $193.69M | $177.91M |
| Operating Cash Flow | $28.61M | $-62.02M | $59.73M | $-46.77M | $-12.94M | $-54.30M | $-38.91M | $-68.73M | $-99.95M | $-37.09M | $-50.04M | $-54.05M | $-52.32M | $13.71M | $-188.00K | $1.37M | $33.12M | $47.35M | $60.19M | $13.48M |
| Capital Expenditure | $- | $- | $- | $- | $-34.00K | $- | $-100.00K | $-152.00K | $-87.00K | $-457.00K | $-880.00K | $-615.00K | $-468.00K | $-261.00K | $-415.00K | $-145.00K | $-944.00K | $-2.11M | $-2.38M | $-1.78M |
| Free Cash Flow | $28.61M | $-62.02M | $59.73M | $-46.77M | $-12.97M | $-54.30M | $-39.02M | $-68.88M | $-100.04M | $-37.55M | $-50.92M | $-54.66M | $-52.79M | $13.45M | $-603.00K | $1.22M | $32.18M | $45.24M | $57.81M | $11.69M |
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
$1.03
Stock Price
$119.37M
Market Cap
306
Employees
Redwood City, CA
Location
Revenue (FY 2024)
$266.96M
3.8% YoY
Net Income (FY 2024)
$28.51M
112.0% YoY
EPS (FY 2024)
$0.25
109.9% YoY
Free Cash Flow (FY 2024)
$-20.44M
88.3% YoY
Profitability
Gross Margin
56.0%
Net Margin
10.7%
ROE
-21.6%
ROA
6.4%
Valuation
P/E Ratio
5.55
P/S Ratio
0.59
EV/EBITDA
4.33
Market Cap
$119.37M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-20.44M
88.3% YoY
Free Cash Flow
$-20.44M
88.3% YoY
Balance Sheet Summary
Total Assets
$448.53M
-28.8% YoY
Total Debt
$231.51M
51.9% YoY
Shareholder Equity
$-131.99M
43.9% YoY
Dividend Overview
No Dividend Data
Coherus BioSciences, Inc. doesn't currently pay dividends.
Coherus BioSciences Dividends
Explore Coherus BioSciences's dividend history, including dividend yield, payout ratio, and historical payments.
Coherus BioSciences News
Read the latest news about Coherus BioSciences, including recent articles, headlines, and updates.
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time– REDWOOD CITY, Calif.
Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs
Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic hepatocellular carcinoma with a 17.2% complete response rate in phase 1 and is now in a phase 2 study. CHRS is still marketing Loqtorzi for nasopharyngeal carcinoma, with Q4'24 revenues of $7.5M representing 29% growth over the prior quarter.
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), has been selected for a poster presentation at the upcoming 2025 AACR Annual Meeting, being held April 25-30, 2025, at McCormick Place Convention Center in Chicago, Illinois.
Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaoker - SVP, Immuno-Oncology Marketing Theresa LaVallee - CDO Rosh Dias - CMO Bryan McMichael - CFO Conference Call Participants Srikripa Devarakonda - Truist Securities Yigal Nochomovitz - Citigroup Colleen Kusy - Baird Michael Nedelcovych - TD Cowen Brian Cheng - JPMorgan Douglas Tsao - H.C. Wainwright Operator Hello everyone and welcome to the Coherus Fourth Quarter Year Ending 2024 Financial Results Conference call.
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures – – UDENYCA® net revenue increased 62% year-over-year – – LOQTORZI® net revenue increased 29% quarter-over-quarter –
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m., Eastern time. A live audio webcast will be accessible through a link posted on the “Events and Presentations” section of the Coherus' investor website: https://investors.coherus.com/events-presentations . A replay of the presentation will be available on this same website for approximately 90 days.
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
Coherus BioSciences focuses on immunotherapy, expanding their PD-1 antibody market, and developing novel treatments for solid tumors, despite maintaining a penny stock valuation. Financially, CHRS holds $97.7 million in cash, $36.6 million in term loans, and $227.9 million in convertible notes, with $70.8 million in net revenues. CHRS is divesting their Udenyca franchise for $483.4 million, with potential milestone payments, following previous sales of Cimerli and Yusimry franchises.
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel Mechanisms in Oncology Panel on December 3, 2024, at 3:15 p.m. ET.
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Jami Taylor - Head of Investor Relations Dennis Lanfear - President and Chief Executive Officer Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Rosh Dias - Chief Medical Officer Bryan McMichael - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Chase & Co. Douglas Tsao - H.C. Wainwright & Co. Billal Jahangiri - Truist Securities Michael Nedelcovych - TD Cowen Colleen Kusy - Robert W.
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until July 7, 2024.
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until June 26, 2024.
Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Denny Lanfear - Chief Executive Officer Paul Reider - Chief Commercial Officer Rosh Dias - Chief Medical Officer Theresa LaVallee - Chief Development Officer Bryan McMichael - Interim Chief Financial Officer Conference Call Participants Michael Nedelcovych - TD Cowen Douglas Tsao - H.C. Wainwright Colleen Kusy - Baird Operator Ladies and gentlemen, thank you for standing by.
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, with debt maturity of May 2029 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif.
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor (ETBR), for the treatment of drug-resistant cancers in the iPROC platform study. Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers.
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. Starting at 5:00 p.m. EDT on May 9, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CHRS.